NVO Jan 2024 80.000 call
| Previous close | 46.50 |
| Open | 46.50 |
| Bid | 50.40 |
| Ask | 55.00 |
| Strike | 80.00 |
| Expiry date | 2024-01-19 |
| Day's range | 46.50 - 46.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
- Zacks
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
- Globe Newswire
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 30 November 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programm
- Motley Fool
3 Healthcare Stocks That Could Set You Up For Life
Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.
